Recurrent venous thromboembolism after deep vein thrombosis -: Incidence and risk factors

被引:463
作者
Hansson, PO [1 ]
Sörbo, J [1 ]
Eriksson, H [1 ]
机构
[1] Univ Gothenburg, Sahlgrenska Hosp, Dept Med, Sect Prevent Med, SE-41685 Gothenburg, Sweden
关键词
D O I
10.1001/archinte.160.6.769
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The recurrence rate after deep vein thrombosis (DVT) is high and the risk factors for recurrent thromboembolic events have only been investigated on a small scale. Objectives: To estimate the cumulative incidence of recurrent venous thromboembolic events after a first or a second DVT and to identify possible risk factors for recurrent venous thromboembolism. Methods: We prospectively followed up 738 consecutive patients with an objectively verified symptomatic DVT for 3.7 to 8.8 years. Medical records and death certificates for all patients were reviewed during follow-up and recurrent DVT and pulmonary embolism were registered. Results: The 5-year cumulative incidence of recurrent venous thromboembolic events was 21.5% (95% confidence interval [CI], 17.7%-25.4%) after a first DVT and 27.9% (95% CI, 19.7%-36.1%) after a second DVT. The 5-year cumulative incidence of fatal pulmonary embolism was 2.6% (95% CI, 1.1%-4.1%) after a first DVT. Proximal DVT (relative risk [RR], 2.40; 95% CI, 1.48-3.88; P < .001), cancer (RR, 1.97; 95% CI, 1.20-3.23; P < .001), and history of a venous thromboembolism (RR, 1.71; 95% CI, 1.16-2.52; P < .01) predicted an independently increased risk of recurrent events in multivariate survival analysis. Postoperative DVT (RR, 0.27; 95% CI, 0.13-0.55; P < .001) and a long duration of oral anticoagulation therapy (RR, 0.95, 95% CI, 0.92-0.98; P < .01) involved a smaller risk of recurrent events. Sex, age, initial antithrombotic therapy, or immobilization did not affect the risk of a recurrent event. Conclusions: The recurrence rate after a symptomatic DVT is high. Patients with proximal DVT, diagnosed cancer, short duration of oral anticoagulation therapy, or a history of thromboembolic events had a higher risk of recurrent events, while patients with postoperative DVT had a lower recurrence rate. This knowledge could help identify patients who might benefit most from prolonged prophylactic treatment in various risk situations.
引用
收藏
页码:769 / 774
页数:6
相关论文
共 20 条
[1]   A POPULATION-BASED PERSPECTIVE OF THE HOSPITAL INCIDENCE AND CASE-FATALITY RATES OF DEEP-VEIN THROMBOSIS AND PULMONARY-EMBOLISM - THE WORCESTER DVT STUDY [J].
ANDERSON, FA ;
WHEELER, HB ;
GOLDBERG, RJ ;
HOSMER, DW ;
PATWARDHAN, NA ;
JOVANOVIC, B ;
FORCIER, A ;
DALEN, JE .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (05) :933-938
[2]  
[Anonymous], 1999, International classification of diseases, clinical modification: Ninth revision, tenth edition
[3]   LONG-TERM OUTCOMES OF DEEP-VEIN THROMBOSIS [J].
BEYTH, RJ ;
COHEN, AM ;
LANDEFELD, CS .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (10) :1031-1037
[4]   Risk of fatal pulmonary embolism in patients with treated venous thromboembolism [J].
Douketis, JD ;
Kearon, C ;
Bates, S ;
Duku, EK ;
Ginsberg, JS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (06) :458-462
[5]  
Eichinger S, 1998, THROMB HAEMOSTASIS, V80, P566
[6]   Deep vein thrombosis and pulmonary embolism in the general population - 'The study of men born in 1913' [J].
Hansson, PO ;
Welin, L ;
Tibblin, G ;
Eriksson, H .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (15) :1665-1670
[7]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[8]   THE MANAGEMENT OF THROMBOSIS IN THE ANTIPHOSPHOLIPID-ANTIBODY SYNDROME [J].
KHAMASHTA, MA ;
CUADRADO, MJ ;
MUJIC, F ;
TAUB, NA ;
HUNT, BJ ;
HUGHES, GRV .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (15) :993-997
[9]   A PROSPECTIVE-STUDY OF THE INCIDENCE OF DEEP-VEIN THROMBOSIS WITHIN A DEFINED URBAN-POPULATION [J].
NORDSTROM, M ;
LINDBLAD, B ;
BERGQVIST, D ;
KJELLSTROM, T .
JOURNAL OF INTERNAL MEDICINE, 1992, 232 (02) :155-160
[10]   Multicenter studies of ultra-high-dose, short-duration streptokinase treatment of deep vein thrombosis [J].
Pilger, E ;
Eriksson, H ;
Grungreiff, K ;
Carlsson, A ;
Talstad, I ;
Anders, O ;
Schuchardt, C ;
Munck, D ;
Lafer, M .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1996, 57 (04) :251-267